Lenvatinib: observed
74 studies: patients on it are followed, or it is given outside a trial. Page 1 of 1. Open to participants first (26), then studies with results posted, then the rest; newest registration first within each.
- Predictive Factors of Long-term Survivor (LTS) of Patients With Recurrent or Metastatic, Radio-iodine Resistant Differentiated Thyroid Cancer (RRDTC) After Lenvatinib: a Multicenter StudyNot yet recruitingNCT07927764Report a problem
- TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)Not yet recruitingNCT07836309Report a problem
- Response to Neoadjuvant Treatment in Locally Advanced Thyroid CancerRecruitingNCT07419932Report a problem
- TACE Versus HAIC, Combined With PD-1 Inhibitors and Lenvatinib for Unresectable Hepatocellular CarcinomaNot yet recruitingNCT07340502Report a problem
- A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world DataNot yet recruitingNCT07156617Report a problem
- The Efficacy of Sequential RT After Triple Therapy for uHCCEnrolling by invitationNCT07052448Report a problem
- Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus PembrolizumabRecruitingNCT06648057Report a problem
- Fecal Microbiota Transplantation in Reversing Drug Resistance in Unresectable HCC (TALENP004)Not yet recruitingNCT06643533Report a problem
- D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICCRecruitingNCT06643208Report a problem
- HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLCRecruitingNCT06632093Report a problem
- Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)RecruitingNCT06602011Report a problem
- Neoadjuvant Triple Therapy for Resectable HCCRecruitingNCT06569498Report a problem
- Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)RecruitingNCT06561399Report a problem
- GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICCRecruitingNCT06505486Report a problem
- HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular CarcinomaRecruitingNCT06333561Report a problem
- Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal HypertensionRecruitingNCT06280313Report a problem
- A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.RecruitingNCT06205732Report a problem
- DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic CholangiocarcinomaRecruitingNCT06194695Report a problem
- Real-World Study on the Efficacy of IBI-322 in Combination With Lenvatinib for the Treatment of Extensive Stage Small Cell Lung CancerRecruitingNCT05991180Report a problem
- Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular CarcinomaRecruitingNCT05717738Report a problem
- Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular CarcinomaRecruitingNCT05713994Report a problem
- A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver CancerNot yet recruitingNCT05660213Report a problem
- Lenvatinib Therapy in HCC Patients After LDLTRecruitingNCT05572528Report a problem
- Effect of Sarcopenia on HCC After Lenvatinib and Anti-PD-1 TreatmentEnrolling by invitationNCT05443230Report a problem
- International Multicentric Study ARON-1RecruitingNCT05287464Report a problem
- Real-world Study for Patients With Advanced Hepatobiliary TumorsRecruitingNCT03892577Report a problem
- First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in SpainActive, not recruitingNCT07852884Report a problem
- Real-World Lenvatinib Sequencing in Unresectable Hepatocellular Carcinoma (uHCC)Active, not recruitingNCT07849660Report a problem
- A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Cancer in Cold RegionsActive, not recruitingNCT07645209Report a problem
- The Application of Locoregional Therapy Combined With Systemic Therapy in the Perioperative Period of Huge Hepatocellular Carcinoma: A Retrospective Cohort StudyCompletedNCT07639294Report a problem
- Radiomics Subtyping to Guide Surgery vs. Maintenance Therapy After HCC DownstagingActive, not recruitingNCT07581769Report a problem
- HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary InvasionActive, not recruitingNCT07466225Report a problem
- CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCCCompletedNCT07449065Report a problem
- Effect of Pre-Transplant Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Patients With Liver TransplantationCompletedNCT07418138Report a problem
- Long-Term Survival With Lenvatinib-Based Therapy in Unresectable Liver CancerActive, not recruitingNCT07298538Report a problem
- Safety and Efficacy of Atezolizumab-Bevacizumab Versus Tyrosin Kinase Inhibitors in Patients With Liver CirrhosisCompletedNCT07193316Report a problem
- SIRT or TACE Plus Lenvatinib and PD-(L)1 Inhibitor in High Burden HCCCompletedNCT06916546Report a problem
- Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCCCompletedNCT06818097Report a problem
- HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCCActive, not recruitingNCT06632106Report a problem
- HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)CompletedNCT06631326Report a problem
- Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based StudyCompletedNCT06599463Report a problem
- Treatment of Metastatic Melanoma with Lenvatinib + Anti-PD1CompletedNCT06586580Report a problem
- Stratification for F-L Therapy After LTCompletedNCT06564103Report a problem
- Intra-Tumoral Vascular Growth Patterns is a Robust Indicator of Adjuvant Therapy Following Liver Resection in HCCActive, not recruitingNCT06461936Report a problem
- Lenvatinib vs Bevacizumab Plus ICIs and HAIC in Unresectable HCCCompletedNCT06435013Report a problem
- Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) PatientsCompletedNCT06345183Report a problem
- Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma: A Real-world Study in ChinaCompletedNCT06315101Report a problem
- Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTTCompletedNCT06265883Report a problem
- Survival Analysis: TACE vs. Combination Therapy in HCCCompletedNCT06261138Report a problem
- VETC is an Effective Marker for Postoperative Adjuvant ImmunotherapyCompletedNCT06253364Report a problem
- Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular CarcinomaActive, not recruitingNCT05889949Report a problem
- Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid CancerCompletedNCT05789667Report a problem
- Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination ImmunotherapyCompletedNCT05579847Report a problem
- TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTTCompletedNCT05535998Report a problem
- HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic CholangiocarcinomaCompletedNCT05489692Report a problem
- Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCCStatus unknownNCT05420922Report a problem
- A Study of Lenvatinib in Combination With Pembrolizumab in Korean PatientsCompletedNCT05375136Report a problem
- TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCCCompletedNCT05332821Report a problem
- TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCCCompletedNCT05332496Report a problem
- Postoperative Adjuvant Therapy of HCC Based on PD-1CompletedNCT05307926Report a problem
- A Study of Lenvima (Lenvatinib) in Korean Unresectable Hepatocellular Carcinoma (uHCC) ParticipantsCompletedNCT05225207Report a problem
- A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular CarcinomaCompletedNCT04763408Report a problem
- Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCCStatus unknownNCT04639284Report a problem
- Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular CarcinomaCompletedNCT04627012Report a problem
- TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)Status unknownNCT04560751Report a problem
- MRI DWI None-Gaussian Model Predicting Early Response to Immunotherapy in Digestive System Malignancies: a Prospective Observational StudyStatus unknownNCT04500990Report a problem
- Safety and Efficacy of Lenvatinib in Subjects With HCC Progression After First Line Treatment With Checkpoint InhibitorsTerminatedNCT04428437Report a problem
- Adjuvant Lenvatinib Prevents Recurrence of High-risk Patients With HBV-related HCC After Liver TransplantationCompletedNCT04415567Report a problem
- A Study of Overall Survival in Participants With Unresectable Hepatocellular CarcinomaCompletedNCT04008082Report a problem
- A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular CarcinomaCompletedNCT03663114Report a problem
- Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in BrazilApproved for marketingNCT03533361Report a problem
- Post-Marketing Surveillance of Lenvima in Korean PatientsCompletedNCT02764554Report a problem
- Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)CompletedNCT02430714Report a problem
- An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid CancerApproved for marketingNCT02211222Report a problem